Archives: Speakers

Dr.Lingling Rogers is a Senior Director of Regulatory Affairs CMC at Urovant Sciences, Inc. in San Diego, CA. She has more than 20 years of experience in the pharmaceutical industry, including 14 years in regulatory affairs CMC. Her expertise includes serving as the company liaison for interactions with global regulatory health authorities; providing regulatory oversight for drug development of small/large molecules and drug device combination products; and leading global regulatory submissions in support of clinical studies, marketing applications, as well as lifecycle management. She has also served on cross-functional due diligence teams conducting critical reviews of third-party regulatory dossiers for potential in-license opportunities. Dr. Rogers holds a M.S. degree in Organic Chemistry from University of San Francisco and a Ph.D. degree in Medicinal Chemistry and Pharmacognosy from Purdue University.

Qiu has over 10 years’ experience in Clinical Study development and execution. He started clinical research journal from Pfizer, which involved in the global clinical trial resulted the successful launch of Viagra (Sildenafil), followed by leading couple of clinical trials in Beijing Novartis Pharma Co., Ltd. Dr. Qiu then switched his gear to clinical validation of diagnostic platforms in academics and IVD industry, including Beckman Coulter and Leica Biosystems. Under his leadership, Leica Biosystems’ Digital Pathology system AT2 DX has been awarded FDA 510(k) clearance 90 days after submission.

Dr. Martin Mendoza serves as the lead for extramural research for the Office of Minority Health and Health Equity (OMHHE), Office of the Commissioner, FDA.  In this capacity, Dr. Mendoza oversees all OMH extramural research which includes projects in the FDA Centers of Excellence in Regulatory Science and Innovation (CERSI) cooperative agreements with Johns Hopkins University, the University of Maryland, Stanford University, the University of California San Francisco, Yale University, and Mayo Clinic. Dr. Mendoza has spoken before Congress in support of OMH’s programs and mission, has authored numerous Congressional response letters and reports, and is also the primary author for OMHHE’s recent FDA guidance document Collection of Race and Ethnicity Data in Clinical Trials.

Prior to joining the FDA, Dr. Mendoza spent several years in the Office of Clinical Research at the National Institute of Neurological Disorders and Stroke (NINDS), NIH.  There, he was part of programmatic management for all NINDS-sponsored clinical trials and oversaw the institute’s extramural human subjects protections activities and the Congressionally-mandated reporting of women and minorities in clinical research.  Previously, Dr. Mendoza was an active researcher within the NIH intramural research program, conducting laboratory-based research at the National Cancer Institute, the National Institute on Aging, and the National Human Genome Research Institute where he served as a genetic mapper for the Human Genome Project.  Dr. Mendoza is a graduate of the University of Maryland Baltimore County and received his doctorate in cancer biology from Johns Hopkins University.

Currently the Director, Outsourcing and Supplier Governance at Halozyme Therapeutics in San Diego.   Dan has over 20 years of outsourcing and supplier governance experience in the bio-pharmaceutical industry including large pharma and bio-tech.

Wes Chaar is an established expert and leading thinker in the fields of Analytics and Data Science, Machine Learning, AI, and Data Fusion fields. He brings more than 20 years of experience driving industry-leading innovation to his role as Catalina’s Chief Data and Analytics Officer, where he is focused on bringing greater value to hundreds of millions of shoppers worldwide, while increasing the efficiency, predictability and responsiveness of retailer and brand marketing initiatives.

Wes is applying his skills in revenue management, pricing, channel distribution, consumer choice modeling, CRM and audience targeting to guide Catalina’s investments that will enhance its one-of-a-kind shopper data analytics engine to drive performance for retailers and brands.

With experience spanning the airline, hospitality, online retail, media and marketing sectors, Wes has been published in a wide array of journals and has presented at conferences spanning the airline, hospitality, online retail and media sectors. He is a member of IEEE, INFORMS and I-COM, where he serves as a board member for both Chief Data Officer and Chief Analytics Officer.

Wes’ work has been recognized with an Emmy for Engineering and Technology (Turner team), the INFORMS Innovative Applications of Analytics Award, the ANA Genius Awards for both (i) Marketing Analytics Science and (ii) Excellence in Pioneering Analytics Innovation, the ARF’s Great Mind Award in Analytics Leadership, and he was a finalist for both the Wagner Prize for Excellence in Operations Research Practice and the Edelman Award for Achievement in Operations Research and Advanced Analytics. Wes earned a Ph.D. from the University of Texas at Austin.